myocardial infarction

A New hs-cTnT Generation 6 Assay Matches Generation 5 for Myocardial Infarction Diagnosis While Labeling Fewer Patients as Myocardially Injured

By MedXY 05/09/2026

In suspected myocardial infarction, hs-cTnT-gen6 showed diagnostic accuracy comparable to gen5, produced fewer myocardial injury classifications, and supported highly sensitive ESC 0/1-hour and 0/2-hour rule-out and rule-in pathways using assay-specific cutoffs.

Clinical Updates news

Epigenetic Regulation of Myocardial Inflammation: The Role of Macrophage PRMT9 and STAT1 Degradation in Acute Myocardial Infarction

By MedXY 05/05/2026

This review explores how PRMT9-mediated symmetric dimethylation of STAT1 serves as a critical check on proinflammatory macrophage activation, offering a novel therapeutic target for mitigating cardiac injury following myocardial infarction.

Cardiology Emergency Medicine news

Revolutionary Sixth-Generation Troponin Assay Doubles Early MI Rule-Out Capacity

By MedXY 04/24/2026

A novel sixth-gen hs-cTnT assay with a 13 ng/L threshold safely identified twice as many low-risk MI patients at ED presentation vs fifth-gen assays, achieving >99.5% NPV in multinational validation.

Cardiology Diabetes & Endocrinology news

STEMI and NSTEMI Are Not the Same in Type 1 Diabetes: Finnish Cohort Reveals Distinct Risk Patterns

By MedXY 04/01/2026

In Finnish adults with type 1 diabetes, STEMI and NSTEMI showed distinct incidence trends and risk profiles. NSTEMI was more common overall and linked to dyslipidemia and advanced microvascular disease, whereas impaired eGFR tracked more with STEMI.

Cardiology news

Breaking the Brake: How Annexin A2 Inhibition Restores Mitophagy and Salvages the Infarcted Heart

By MedXY 03/25/2026

This study identifies Annexin A2 as a critical negative regulator of PHB2-mediated mitophagy in myocardial infarction. By promoting PHB2 degradation via the TRIM29 ligase, ANXA2 exacerbates cardiac injury. Inhibiting ANXA2 restores mitochondrial homeostasis, offering a promising therapeutic avenue for heart failure.

Cardiology news

Unlocking Mitochondrial Resilience: How Annexin A2 Inhibition Protects the Infarcted Heart

By MedXY 03/21/2026

Researchers identify Annexin A2 as a key inhibitor of mitophagy in the heart. By blocking the mitophagy receptor PHB2, ANXA2 exacerbates cardiac injury after myocardial infarction. This study demonstrates that targeting ANXA2 restores mitochondrial homeostasis and improves cardiac remodeling.

Cardiology Internal Medicine news

Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study

By MedXY 03/09/2026

This phase 2 trial demonstrates that varenicline, a partial nAChR agonist, significantly reduces premature ventricular complexes and nonsustained ventricular tachycardia in post-myocardial infarction patients, offering a novel therapeutic target for cardiac arrhythmias.

Cardiology news

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

By MedXY 03/09/2026

The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor bleeding risk, suggesting a need for cautious clinical application.

Cardiology news

ALDH2 rs671 Variant and Thrombotic Risk: Unveiling a New Target for Precision Antiplatelet Therapy in East Asian Populations

By MedXY 03/02/2026

Recent research reveals that the common ALDH2 rs671 genetic variant significantly enhances platelet activation and arterial thrombosis through aldehyde accumulation, reactive oxygen species, and ACAD10-mediated mitophagy, identifying ALDH2 as a potential novel target for personalized antiplatelet strategies in East Asian patients.

Cardiology Internal Medicine news

Long-Term Prognosis of Acute Myocardial Infarction Caused by Isolated Diffuse Coronary Artery Ectasia

By MedXY 03/02/2026

Patients with myocardial infarction due to isolated coronary artery ectasia face a significantly higher risk of recurrent MI and stent thrombosis compared to those without ectasia, highlighting the need for specialized long-term management.

Cardiology news

Isolated Coronary Artery Ectasia: A High-Risk Phenotype Associated with Doubled Recurrent Infarction Rates

By MedXY 03/02/2026

A retrospective study reveals that patients with myocardial infarction caused by isolated coronary artery ectasia face significantly higher risks of recurrence and stent thrombosis compared to those without ectasia, highlighting a critical need for tailored antithrombotic strategies in this unique patient population.

Cardiology news

PRMT9 and Heart Recovery: A New Frontier in Macrophage Modulation and STAT1 Degradation

By MedXY 03/02/2026

Researchers have discovered that the protein PRMT9 plays a vital role in healing the heart after a myocardial infarction by controlling inflammatory macrophages. By promoting the degradation of the STAT1 protein, PRMT9 reduces tissue damage and improves cardiac function.

Cardiology Clinical Updates news

Orchestrating Cardiac Repair: The CCL1-CCR8 Axis as a Master Regulator of Regulatory T Cell Recruitment Post-Myocardial Infarction

By MedXY 03/01/2026

This review explores the discovery of a two-phase specialization process where CCR8+ regulatory T cells, recruited via the macrophage-derived CCL1 axis, mitigate inflammation and promote cardiac repair following myocardial infarction.

Cardiology news

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

By MedXY 02/20/2026

Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.

Cardiology Nephrology news

Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial

By MedXY 01/17/2026

A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without increasing the risk of contrast-associated acute kidney injury.

Cardiology Diabetes & Endocrinology news

Beyond the Heart: Why Metabolic Gains Are the True Drivers of GLP-1RA Cardioprotection

By MedXY 12/30/2025

A robust Mendelian randomization study demonstrates that the reduced risk of myocardial infarction associated with GLP-1 receptor agonists is primarily mediated by improvements in HbA1c, BMI, and lipid profiles, rather than direct cardiac effects.

Cardiology news

Refining Risk: Clinical and Angiographic Predictors of Postprocedural Troponin Elevation in Elective PCI

By MedXY 12/30/2025

A comprehensive analysis of over 10,000 patients identifies key risk factors for post-PCI troponin increase, highlighting the protective role of intravascular imaging and the prognostic impact of different myocardial infarction definitions.

Cardiology news

Troponin Assay Transitions: Increased Clinical Burden Without Improved Cardiovascular Outcomes

By MedXY 12/24/2025

Switching from high-sensitivity troponin I to T significantly increases diagnoses of myocardial injury and hospital admissions without improving long-term cardiovascular outcomes, while low-threshold troponin I remains a safe tool for rapid rule-out.

Cardiology Neurology news

Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients

By MedXY 12/16/2025

A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.

Cardiology news

Intracoronary Wharton’s Jelly Mesenchymal Stem Cells After STEMI Reduce Incident Heart Failure: Phase 3 PREVENT-TAHA8 Results

By MedXY 11/21/2025

A phase 3 randomized trial found intracoronary infusion of allogeneic Wharton’s jelly mesenchymal stem cells (WJ-MSCs) after STEMI reduced new-onset heart failure and HF readmissions and improved LVEF versus standard care over a median 33-month follow-up.